Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00137839
Status:
COMPLETED
Last Update Posted:
2019-12-17
First Post:
2005-08-29
Brief Title:
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Sponsor:
Pasi A Janne MD PhD
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
A Phase II Study of Erlotinib OSI-774 Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung
Status:
COMPLETED
Status Verified Date:
2019-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to figure out what effects good or bad the investigational drug agent called Tarceva erlotinib OSI-774 has on women with previously untreated adenocarcinoma
Detailed Description:
Patients will start taking Tarceva daily by mouth on Day 1 and will continue taking this medication daily at home until participation in the study ends
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None